These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 38542455)

  • 1.
    Mak AL; Augustijn QJJ; Heymann CJF; Havik S; Verdoes X; Rios-Morales M; Bosmans LA; Verheij J; Meijnikman AS; de Jonge PA; Herrema H; de Vos WM; Nieuwdorp M; Grefhorst A; Holleboom AG
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease.
    Martínez-Sanz J; Talavera-Rodríguez A; Díaz-Álvarez J; Rosas Cancio-Suárez M; Rodríguez JM; Alba C; Montes ML; Martín-Mateos R; Burgos-Santamaría D; Moreno S; Serrano-Villar S; Sánchez-Conde M
    Front Immunol; 2023; 14():1297378. PubMed ID: 38162648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duodenal
    Koopen A; Witjes J; Wortelboer K; Majait S; Prodan A; Levin E; Herrema H; Winkelmeijer M; Aalvink S; Bergman JJGHM; Havik S; Hartmann B; Levels H; Bergh PO; van Son J; Balvers M; Bastos DM; Stroes E; Groen AK; Henricsson M; Kemper EM; Holst J; Strauch CM; Hazen SL; Bäckhed F; De Vos WM; Nieuwdorp M; Rampanelli E
    Gut; 2022 Aug; 71(8):1577-1587. PubMed ID: 34697034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helicobacter pylori infection exacerbates metabolic dysfunction-associated steatotic liver disease through lipid metabolic pathways: a transcriptomic study.
    Chen X; Peng R; Peng D; Liu D; Li R
    J Transl Med; 2024 Jul; 22(1):701. PubMed ID: 39075482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut commensal Kineothrix alysoides mitigates liver dysfunction by restoring lipid metabolism and gut microbial balance.
    Choi KJ; Yoon MY; Kim JE; Yoon SS
    Sci Rep; 2023 Sep; 13(1):14668. PubMed ID: 37674003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
    Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The gut microbiome modulates the impact of Anaerobutyricum soehngenii supplementation on glucose homeostasis in mice.
    Hutchison ER; Yen MI; Peng HW; Davis CR; Vivas EI; Tallon MM; Bui TPN; de Vos WM; Yen CE; Nieuwdorp M; Rey FE
    Res Sq; 2024 May; ():. PubMed ID: 38746233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidative stress in metabolic dysfunction-associated steatotic liver disease (MASLD): How does the animal model resemble human disease?
    Jakubek P; Kalinowski P; Karkucinska-Wieckowska A; Kaikini A; Simões ICM; Potes Y; Kruk B; Grajkowska W; Pinton P; Milkiewicz P; Grąt M; Pronicki M; Lebiedzinska-Arciszewska M; Krawczyk M; Wieckowski MR
    FASEB J; 2024 Feb; 38(3):e23466. PubMed ID: 38318780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid Trem2 ameliorates the progression of metabolic dysfunction-associated steatotic liver disease by regulating macrophage pyroptosis and inflammation resolution.
    Yu W; Zhang Y; Sun L; Huang W; Li X; Xia N; Chen X; Wikana LP; Xiao Y; Chen M; Han S; Wang Z; Pu L
    Metabolism; 2024 Jun; 155():155911. PubMed ID: 38609037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of adipose tissue and subsequent liver tissue hypoxia in obesity and early stage metabolic dysfunction associated steatotic liver disease.
    Van Eyck A; Kwanten WJ; Peleman C; Makhout S; Van Laere S; Van De Maele K; Van Hoorenbeeck K; De Man J; De Winter BY; Francque S; Verhulst SL
    Int J Obes (Lond); 2024 Apr; 48(4):512-522. PubMed ID: 38142264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.
    Aggeletopoulou I; Tsounis EP; Triantos C
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in liver metabolic pathways demonstrate efficacy of the combined dietary and microbial therapeutic intervention in MASLD mouse model.
    Iannone V; Babu AF; Lok J; Gómez-Gallego C; D'Auria G; Vazquez-Uribe R; Vaaben TH; Bongers M; Mikkonen S; Vaittinen M; Tikkanen I; Kettunen M; Klåvus A; Sehgal R; Kaminska D; Pihlajamaki J; Hanhineva K; El-Nezami H; Sommer MOA; Kolehmainen M
    Mol Metab; 2023 Dec; 78():101823. PubMed ID: 37839774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with Anaerobutyricum soehngenii: a pilot study of safety and dose-response effects on glucose metabolism in human subjects with metabolic syndrome.
    Gilijamse PW; Hartstra AV; Levin E; Wortelboer K; Serlie MJ; Ackermans MT; Herrema H; Nederveen AJ; Imangaliyev S; Aalvink S; Sommer M; Levels H; Stroes ESG; Groen AK; Kemper M; de Vos WM; Nieuwdorp M; Prodan A
    NPJ Biofilms Microbiomes; 2020 Mar; 6(1):16. PubMed ID: 32221294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted metabolomics reveals plasma short-chain fatty acids are associated with metabolic dysfunction-associated steatotic liver disease.
    Thing M; Werge MP; Kimer N; Hetland LE; Rashu EB; Nabilou P; Junker AE; Galsgaard ED; Bendtsen F; Laupsa-Borge J; McCann A; Gluud LL
    BMC Gastroenterol; 2024 Jan; 24(1):43. PubMed ID: 38262952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reclassification of Eubacterium hallii as Anaerobutyricum hallii gen. nov., comb. nov., and description of Anaerobutyricum soehngenii sp. nov., a butyrate and propionate-producing bacterium from infant faeces.
    Shetty SA; Zuffa S; Bui TPN; Aalvink S; Smidt H; De Vos WM
    Int J Syst Evol Microbiol; 2018 Dec; 68(12):3741-3746. PubMed ID: 30351260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus.
    Forlano R; Martinez-Gili L; Takis P; Miguens-Blanco J; Liu T; Triantafyllou E; Skinner C; Loomba R; Thursz M; Marchesi JR; Mullish BH; Manousou P
    Gut Microbes; 2024; 16(1):2304157. PubMed ID: 38235661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicological safety evaluation of live Anaerobutyricum soehngenii strain CH106.
    Seegers JFML; Gül IS; Hofkens S; Brosel S; Schreib G; Brenke J; Donath C; de Vos WM
    J Appl Toxicol; 2022 Feb; 42(2):244-257. PubMed ID: 34184753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COMPARISON OF GUT MICROBIOTA IN ALCOHOLIC AND METABOLIC-DYSFUNCION ASSOCIATED STEATOTIC LIVER DISEASE IN ANIMAL MODELS.
    Perlin CM; Longo L; Thoen RU; Uribe-Cruz C; Álvares-DA-Silva MR
    Arq Gastroenterol; 2024; 61():e23100. PubMed ID: 38511793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments.
    Pirola CJ; Landa MS; Schuman M; García SI; Salatino A; Sookoian S
    Clin Mol Hepatol; 2024 Oct; ():. PubMed ID: 39391907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of carnosine supplementation on markers for the pathophysiological development of metabolic dysfunction-associated steatotic liver disease in a diet-induced model.
    Grandini NA; Costa MR; Gregolin CS; Siqueira JS; Vieira TA; Togneri Ferron AJ; Francisqueti-Ferron FV; Romualdo GR; Lúcia Dos Anjos Ferreira A; Aldini G; Corrêa CR; Moreto F
    Mol Cell Endocrinol; 2024 Mar; 582():112138. PubMed ID: 38147954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.